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cpm Counts per minute 
eGFP Enhanced green fluorescent protein
ELISA Enzyme-linked immunosorbent assay
FACS Fluorescence-assisted cell sorting
FOXP3 Factor forkhead-box protein 3
GMP Good medical practice 
GvHD Graft-versus-host disease
HUVEC Human umbilical cord endothelial cell
i.p. Intraperitoneal 
i.v. Intravenous 
MTT 3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide 
OCT Optimal cutting temperature
PBMC Peripheral blood mononuclear cell
RAG Recombination activating gene
scFv Single-chain variable fragment
SD Standard deviation 
SE Standard error of the mean
Teff Effector T cell 
Treg Regulatory T cells 
 
ABSTRACT 
Regulatory T cell (Treg) therapy using recipient-derived Tregs expanded ex vivo is currently being 
investigated clinically by us and others as a means of reducing allograft rejection following organ 
transplantation. Data from animal models has demonstrated that adoptive transfer of allospecific 
Tregs offers greater protection from graft rejection compared to polyclonal Tregs. Chimeric antigen 
receptors (CAR) are clinically-translatable synthetic fusion proteins which can redirect the specificity 
of T cells towards designated antigens. We used CAR technology to redirect human polyclonal Tregs 
towards donor-MHC class I molecules which are ubiquitously expressed in allografts. Two novel HLA-
A2-specific CARs were engineered: one comprising a CD28-CD3ζ signalling domain (CAR) and one 
lacking an intracellular signalling domain (ΔCAR). CAR Tregs were specifically activated and 
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significantly more suppressive than polyclonal or ΔCAR Tregs in the presence of HLA-A2, without 
eliciting cytotoxic activity. Furthermore, CAR and ΔCAR Tregs preferentially transmigrated across 
HLA-A2-expressing endothelial cell monolayers. In a human skin xenograft transplant model, 
adoptive transfer of CAR Tregs alleviated the alloimmune-mediated skin injury caused by 
transferring allogeneic PBMCs more effectively than polyclonal Tregs. Our results demonstrated that 
the use of CAR technology is a clinically applicable refinement of Treg therapy for organ 
transplantation.  
 
INTRODUCTION 
The long-term benefits of organ transplantation are hindered by graft rejection (1-5), a detrimental 
process driven by alloreactive T cells which recognise donor MHC antigens via the direct, indirect 
and semi-direct pathways of allorecognition (3, 6). Current immunosuppressive regimens target the 
direct pathway and reduce acute allograft rejection (7) but are associated with severe side-effects 
(8) and do not effectively prevent chronic rejection (2, 9), thus the half-life of allografts remains 
limited to  
10-15 years (10, 11). 
Thymus-derived regulatory T cells (tTregs) are immunosuppressive T cells with a fundamental role in 
the maintenance of tolerance in vivo (12-15). These cells are characterised in humans as 
CD4+CD25hiCD127lo and constitutively express the transcription factor forkhead-box protein 3 
(FOXP3) (7, 12, 16). In rodent models, Tregs significantly prolong the survival of skin (17-19) and 
heart (4) allografts and in humans, correlations between the proportion of Tregs within allografts 
and graft survival have been observed (20-22). With the safety of Treg therapy having been 
demonstrated in the contexts of graft-versus-host disease (GvHD) (23-26) and Type I diabetes (27, 
28), we are conducting Phase I/II clinical trials to investigate the therapeutic potential of adoptive 
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polyclonal Treg therapy to promote tolerance in kidney (the ONE Study: NCT02129881) and liver 
(ThRIL: NCT02166177) transplant recipients (29, 30). 
However, we (4, 17, 19, 31), and others (32, 33), have demonstrated in animal models that 
allospecific Tregs are superior to polyclonal Tregs at reducing graft rejection, upon adoptive transfer. 
Murine Tregs expanded with allogeneic antigen presenting cells (APC) (direct allospecificity) and/or 
transduced to express an allospecific TCR (indirect allospecificity) prolonged graft survival 
significantly more effectively than polyclonal Tregs. These findings were confirmed using human 
Tregs expanded with allogeneic dendritic cells (19) and B cells (31, 34) in human skin xenograft 
transplant models. As such, clinical trials are assessing the safety and efficacy of Tregs with direct 
allospecificity in kidney (DART: NCT02188719) and liver (delta: NCT02188719 and NCT01624077) 
transplant recipients. Here, we investigated whether allospecificity may be conferred onto Tregs 
using chimeric antigen receptors (CAR) (35). 
CARs are synthetic fusion proteins capable of redirecting the specificity of T cells towards desired 
antigens. Classical CARs comprise an extracellular antigen-targeting moiety which binds a specific 
antigen in an MHC-independent manner and a series of customised intracellular TCR and co-
stimulatory signalling domains. As such, CARs translate the binding of specific antigens into the 
activation of desired signalling cascades (36). CARs are primarily used clinically to generate tumour 
antigen-specific T cells (37-43). However, pre-clinical studies have shown the efficacy of CAR-
modified Tregs for the treatment of colitis (16, 44, 45) and multiple sclerosis (46). The functionality 
of CARs has also been demonstrated in human Tregs (47, 48), most recently as a means of protecting 
against xeno-GvHD (49). However, to date, nobody has demonstrated the capacity of CAR Tregs to 
protect from solid transplant rejection. 
In this study, we applied CAR technology to generate allospecific Tregs with the aim of promoting 
organ transplant tolerance. We redirected human CD4+CD25+CD127loFOXP3+ Tregs towards an MHC 
class I molecule (HLA-A2), an alloantigen which is ubiquitously expressed in an allograft, with the 
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hypothesis that they would be more potent than polyclonal Tregs at protecting from graft rejection, 
upon adoptive transfer. 
MATERIALS AND METHODS 
CAR generation 
A previously described (50) HLA-A2-specific single chain variable fragment (scFv) sequence (3PB2 VH 
and DPK1 VL) was validated by immunoprecipitation (data not shown) and cloned upstream of i) a 
9E10 cMyc epitope; ii) a human CD28 hinge/transmembrane domain; iii) a human CD28-CD3ζ 
signalling domain; and iv) an enhanced green florescent protein (eGFP) open reading frame (ORF) in 
a second generation pLNT/SFFV lentiviral plasmid (provided by Prof. Adrian Thrasher; UCL, London, 
UK). A truncated CAR (ΔCAR) was generated by removing the CD28-CD3ζ signalling domain from the 
full-length CAR-eGFP fusion. All plasmids were verified by sequencing (Beckman Coulter Genomics). 
 
Human CD4+CD25+ Treg and CD4+CD25‒ Teff isolation and culture 
Anonymised healthy donor peripheral blood was obtained from the National Blood Service (NHS 
Blood and Transplantation, Tooting, London, UK) with informed consent and ethical approval 
(Institutional Review Board of Guy’s Hospital; reference 09/H0707/86). CD4+ T cells were enriched 
using RosetteSep™ (StemCell Technologies) after which CD4+CD25+ Tregs and CD4+CD25‒ Teffs were 
separated using CD25 MicroBeads II (Miltenyi Biotec). 
Tregs/Teffs were activated with anti-CD3/CD28 beads (1:1 bead:cell ratio; Thermo Fisher Scientific) 
and cultured in X-vivo 15 (Lonza) supplemented with 5% human AB serum (BioSera). Treg were 
cultured with 100 nM rapamycin (LC-Laboratories) and 1,000 U/mL recombinant IL-2 (Proleukin-
Novartis) whilst Teffs were cultured with 100 U/mL IL-2 only. 
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Flow cytometry and cell sorting 
Cells were stained in phosphate buffered saline (PBS) supplemented with 1% heat-inactivated foetal 
calf serum (FCS) and 5 mM EDTA (all from Thermo Fisher Scientific) using fluorescently-conjugated 
antibodies specific for HLA-A2 (BB7.2), CD4 (OKT4), FOXP3 (PCH101), CD39 (eBioA1), CD69 (H1.2F3) 
(all from eBioscience), CD25  (4E3 or 2A3), CTLA-4 (BNI3) (all from BD Biosciences) CD127 (A019D5), 
CCR4 (L291H4), CCR9 (L053E8), CCR10 (5688-5), CD62L (DREG-56), integrin β7 (FIB504), CLA (HECA-
452), HLA-DR (all from BioLegend), HLA-A2 (REA142) (Miltenyi-Biotec) and HLA class I (Tu149) 
(Thermo Fisher Scientific). Cells were stained with PE-conjugated HLA-A*0201/CINGVCWTV and HLA-
B*0702/DPRRRSRNL dextramers (Immudex) provided by Dr. Marc Martinez-Llordella; KCL, London, 
UK. Dead cells were excluded using live/dead near-IR staining (Thermo Fisher Scientific). Intracellular 
staining was performed using the eBioscience Fix/Perm kit. Cells were acquired and sorted using an 
LSRFortessa II and FACSAria II (BD), respectively. Data was analysed using FlowJo 7 or 10 (Tree Star). 
 
Immortalised cell line culture 
HEK293T, MCF-7, and T-47D epithelial cells were grown in DMEM-based media. B-Lymphoblastoid 
cell lines (B-LCL) and K562s (donated by Dr. Marc Martinez-Llordella) were grown in RPMI-based 
media. All culture medias were supplemented with 10% heat-inactivated FCS, 100 units/mL 
penicillin, 100 μg/mL streptomycin and 2 mM L-glutamine (all from Thermo Fisher Scientific). HLA-
transfected K562 cultures were supplemented with 5 μg/mL neomycin (Thermo Fisher Scientific). All 
cells were grown at 37°C in the presence of 5% (v/v) CO2. 
 
Lentivirus production and Treg/Teff transduction 
HEK293T cells were co-transfected with pLNT/SFFV-CAR-eGFP or pLNT/SFFV-ΔCAR-eGFP (Figure 1A), 
pΔ8.91 and pCMV-VSV-G plasmids at a mass ratio of 4:3:1 using polyethylenimine (3:1 PEI:DNA w/w; 
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Sigma-Aldrich). Viral supernatant was harvested 48-56 hours post-transfection and lentiviral 
particles were concentrated using PEG-it™ (System Biosciences). Tregs/Teffs were transduced in 
RetroNectin-treated plates (50 µg/μL; Takara Bio Inc.) 3 days post-isolation using 4-fold 
concentrated viral supernatant. eGFP+ cells were purified by FACS 7 days post-transduction. 
 
T cell/epithelial cell co-culture 
Teffs/Tregs were co-cultured overnight with confluent MCF-7 or T-47D cell monolayers. Culture 
supernatants were collected to measure IL-2, interferon (IFN)γ and IL-10 production by cytokine-
specific enzyme-linked immunosorbent assays (ELISA) (eBioscience). Monolayers were washed and 
the viability of the monolayer cells was determined by 3-(4,5-Dimethylthiazol-2-yl)-2,5-
Diphenyltetrazolium Bromide (MTT) assay. Absorbance was measured at 560 nm. Results are shown 
as percent viability relative to monolayers cultured alone. 
 
Suppression assays 
Tregs were co-cultured with autologous CD4+CD25‒ Teff responders which were labelled with 
CellTrace Violet (CTV; Thermo Fisher Scientific) and activated with anti-CD3/CD28 beads (1:40 
bead:cell ratio) or irradiated (12,000 cGy) allogeneic B-LCLs (3:1 T:B-LCL ratio); DBB (HLA-A2+DR7+), 
MOU (HLA-A2–DR7+), SPO (HLA-A2+DR11+) and BM21 (HLA-A2–DR11+). Teff CTV dilution was 
measured after 5 days using flow cytometry. Results are shown as percent suppression (inverse of 
percent Teff proliferation) relative to Teffs cultured alone. 
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In vitro flow chamber assay 
Primary human umbilical vein endothelial cells (HUVECs) were isolated by collagenase digestion 
using ethically-approved protocols (East London & The City Local Research Ethics Committee 
reference 05/Q0603/34 ELCHA). HUVECs were stimulated with 15 ng/mL IFNγ for 72 hours (R&D) 
prior to experimentation and seeded in μ-Slides VI 0.4 (Ibidi) coated with 0.5% bovine gelatin. Tregs 
were suspended at 1x106 cells/mL in PBS (with Ca2+ and Mg2+) and flowed across HUVEC layers using 
a shear stress of 1 dyn/cm2. The number of Tregs which migrated in 10 second frames was assessed. 
 
Animals 
BALB/c recombination activating gene (RAG)2–/–γc–/– (BRG) mice were maintained under sterile 
conditions (Biological Services Unit, New Hunt’s House, King’s College London). All procedures were 
performed in accordance with all legal, ethical and institutional requirements (PPL70/7302). 
 
Human skin xenograft transplant model 
Human skin was obtained from routine surgical procedures with informed consent and ethical 
approval (Guy’s and St. Thomas’ NHS Foundation Trust and King’s College London; reference 
06/Q0704/18). Donor HLA-A2 expression was determined by flow cytometry, staining skin-derived 
cells obtained by collagenase digestion (100 µg/mL, Sigma-Aldrich). 1.5 cm2 split-thickness skin grafts 
were transplanted onto 10-11 week old recipient BRG mice as previously described (19) and mice 
were administered 100 µg anti-mouse Gr-1 (BioXCell) intraperitoneally every 3-4 days. After 5-6 
weeks (Figure S4), mice were injected intravenously with 5x106 PBMCs ± 1x106 Tregs. Skin grafts 
were harvested for histological analysis 5 weeks following PBMCs/Tregs transfer. 
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Histological analysis of human skin 
Skin grafts were frozen in optimum cutting temperature (OCT) (Thermo Fisher Scientific). 8 or 16 µm 
thick sections were fixed in 4% paraformaldehyde, blocked with a mixture of 10% donkey serum, 
0.1% fish skin gelatin, 0.1% Triton X-100 and 0.5% Tween-20 (all from Sigma-Aldrich) in PBS and 
stained with the following antibodies: anti-human CD3 (polyclonal rabbit, DAKO), anti-FOXP3 
(236A/E7, Abcam), anti-CD45 (HI30, eBioscience), anti-involucrin (CY5, Sigma-Aldrich), anti-human 
CD31 and Ki67 (both polyclonal rabbit, Abcam). Sections were stained with secondary donkey anti-
mouse Alexa Fluor®555 and anti-rabbit Alexa Fluor®488 or Alexa Fluor®647 antibodies with 4-6-
diamidino-2-phenylindole (DAPI) (all from Thermo Fisher Scientific) and mounted with Fluorescence 
Mounting Medium (DAKO). Maximum intensity projection images consisting of 10 z-stacks (1.1 µm 
apart) were acquired at x20 magnification using a C2+ point scanning confocal microscope (Nikon) 
and analysed/quantified with NIS Elements and FIJI imaging software (51). 
 
Statistical analysis 
Data shown is mean ± standard error (SEM) or mean ± standard deviation (SD). Statistical 
significance was determined using two-tailed paired Student’s t-tests or analysis of variance 
(ANOVA) with the Tukey multiple comparison post-hoc test. *=p<0.05, **=p<0.01, ***=p<0.001 and 
****=p<0.0001. 
 
RESULTS 
Generation and validation of a novel HLA-A2-specific CAR 
A HLA-A2-specific CAR incorporating a human CD28-CD3ζ signalling domain was generated using a 
patient-derived HLA-A2-specific scFv sequence (50) (Figure 1A-B). A second generation CAR was 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
selected based on the superior function of these CARs relative to first generation CARs (52-55) and 
the importance of CD28 signalling for Treg activation (56). To investigate the importance of this 
signalling domain, a HLA-A2-specific CAR lacking a CD28-CD3ζ signalling domain (ΔCAR) was also 
generated (Figure 1A-B). This control was selected, as opposed to a CAR containing a scrambled 
ectodomain, to ascertain whether the ability of the Tregs to engage HLA-A2 was sufficient to elicit 
protection in vivo or whether Treg activation via the CAR was also necessary. 
To confirm the functionality and HLA-A2-specificity of these CARs, polyclonal CD4+CD25‒ effector T 
cells (Teffs) were transduced with VSV-G-pseudotyped lentiviral particles containing the CAR or the 
ΔCAR constructs with an efficiency of 40-80% (54.3-62.8 ± 11.9%; Figure 1C). eGFP+ Teffs were 
purified by cell sorting and co-cultured overnight with confluent monolayers of MCF-7 and T-47D 
cells, breast cancer epithelial cells which differentially expressed HLA-A2 (Figure 1D and (57)). CAR 
Teffs specifically destroyed HLA-A2+ monolayers but left HLA-A2– monolayers intact (Figure 1E). 
Compared to epithelial cells cultured alone, CAR Teffs killed 80.8 ± 4.2% of the HLA-A2+ cells but not 
the HLA-A2– cells (Figure 1F). Untransduced and ΔCAR Teffs exhibited no detectable level of 
cytotoxicity. High levels of IL-2 (Figure 1G) and IFNγ (Figure 1H) were also produced by the CAR Teffs 
during co-culture with HLA-A2+ cells. These results demonstrated that CAR expression by T cells 
mediated specific recognition of HLA-A2 antigens resulting in Teff activation, cytotoxicity and 
cytokine production. 
 
Human CD4+CD25+ Tregs maintained their phenotype and function following lentiviral 
CAR transduction 
Having validated the CARs in Teffs, we next assessed whether lentiviral transduction influenced the 
phenotype and/or suppressive capacity of human Tregs. CD4+CD25+ Tregs were enriched using GMP-
compatible protocols (58) from the peripheral blood of healthy HLA-A2‒ donors with a purity of 
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approximately 90% (89.5 ± 4.4%, n=16; Figure S1A). A high proportion of the cells were FOXP3+ with 
a low expression of CD127 (Figure S1B). These cells were activated using anti-CD3/CD28 beads and 
expanded in the presence of 1,000 U/mL recombinant human IL-2 and 100 nM rapamycin (29, 58). 
Tregs were transduced with the CAR or ΔCAR construct 72 hours post-activation (Figure 2A), with 
efficiencies of 30-80% (55.1-69.2 ± 20.3%, n=15; Figure 2B). eGFP+ Tregs were purified by flow 
sorting 7 days post-transduction (Figure 2B) and expanded for an additional 10 days (Figure 2A). All 
eGFP+ Tregs were shown to have a detectable level of CAR expression on the cell surface (Figure 2B) 
which facilitated in the specific recognition of a HLA-A2-based dextramer but not an irrelevant HLA-
B7-based dextramer (Figure 2C). Furthermore, engagement of HLA-A2 was shown to specifically 
activate CAR Tregs but not untransduced or ΔCAR Tregs (Figure 2D and Figure S2). 
Following expansion, >95% (95.3-97.8 ± 4.7%) of the transduced Tregs remained eGFP+. These cells 
exhibited a similar phenotype to untransduced Tregs (Figure 2E and Figure S3A); they remained 
CD4+CD25+CD127lo with a high proportion expressing FOXP3 (94.2-95.8 ± 7.3%), CTLA-4 (91.3-95.3 ± 
3.1%) and CD39 (72.4-81.7 ± 16.3%). Treg expression of specific homing receptors was also unaltered 
(Figure 2F and Figure S3B). The Tregs expressed the skin homing molecules CCR4 (96.7-98.8 ±3.2%) 
and cutaneous lymphocyte antigen (CLA) (48.4-51.0 ± 26.4%) but few cells expressed CCR10 (0.6-1.5 
± 0.7%), as previously published (58). All cells expressed CD62L (93.7-95.6 ± 3.9%) and with regards 
to gut homing, a high proportion expressed integrin β7 (91.7-93.2 ± 5.9%) but few cells expressed 
CCR9 (1.1-1.7 ± 1.0%). 
To assess the suppressive capacity of the Tregs, untransduced, CAR and ΔCAR Tregs were co-
cultured with CTV-labelled autologous CD4+CD25‒ responder Teffs in the presence of anti-CD3/28 
beads for 5 days. At a 1:32 Treg:Teff ratio, untransduced, CAR and ΔCAR Tregs inhibited Teff 
proliferation by 43.0 ± 4.1%, 44.8 ± 5.4% and 39.4 ± 5.7%, respectively, proving the potency of these 
cells and indicating that the Treg function following transduction was unaltered. 
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Taken together, these results demonstrated that human Tregs isolated and expanded with clinically-
relevant protocols maintained their phenotype and function following transduction with VSV-G-
pseudotyped lentiviral particles. 
 
CAR-mediated alloantigen recognition by human Tregs enhanced their potency 
To assess whether CAR Tregs were functionally superior to untransduced (polyclonal) Tregs in the 
presence of HLA-A2, Tregs were co-cultured with CTV-labelled CD4+CD25‒ responder Teffs and  
allogeneic B-LCLs which differentially expressed HLA-A2 as APCs. The suppressive profile of the 
polyclonal Tregs cultured with HLA-A2+ and HLA-A2‒ B-LCLs was identical (Figure 3A) whilst CAR 
Tregs inhibited Teff proliferation significantly more effectively (p-values 0.0082-1.1x10‒5) in the 
presence of HLA-A2+ B-LCLs, compared to HLA-A2‒ B-LCLs (Figure 3B). At a 1:32 and 1:64 Treg:Teff 
ratio, CAR Tregs inhibited Teff proliferation by 62.8 ± 5.2% and 38.1 ± 3.6%, respectively, in the 
presence of HLA-A2 but only 35.8 ± 3.5% and 16.9 ± 3.4%, respectively, in the absence of HLA-A2. 
ΔCAR Tregs were significantly more suppressive in the presence of HLA-A2 at Treg:Teff ratios of 1:2 
(p=0.041) and a 1:32 (p=0.027) (Figure 3C). This minor increase in suppressive ability may have been 
due to the antigen-targeting moiety of the ΔCAR facilitating an interaction between the ΔCAR Tregs 
and the HLA-A2+ APCs, bringing the Treg into the vicinity of the Teff:B-LCL interaction. 
Tregs can function by secreting granzyme and perforin (59, 60). To exclude the risk of unwanted 
cytotoxicity, Tregs were co-cultured with confluent monolayers of HLA-A2+ and HLA-A2– epithelial 
cells, as previously described (Figure 1). Unlike CAR Teffs, CAR Tregs exhibited no detectable level of 
cytotoxicity towards the HLA-A2+ cells (Figure 3D). IL-2 secretion was undetectable in all conditions 
analysed (data not shown) and low levels of IFNγ (221 ± 80 pg/µL; Figure 3E) were produced by CAR 
Tregs co-cultured with HLA-A2+ monolayers. In contrast, these cells produced significantly high levels 
of the immunosuppressive cytokine IL-10 (1,055 ± 78 pg/µL) compared to polyclonal Tregs (not 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
detected) and ΔCAR Tregs (8 ± 1 pg/µL) (Figure 3F), suggesting that in vivo, CAR Tregs would 
contribute to the establishment of an intragraft immunosuppressive milieu in HLA-A2+ allografts. 
Given the importance of Treg trafficking in vivo, we investigated whether the expression of HLA-A2 
by endothelial cells influenced the rate with which CAR Tregs transmigrated (61). Relative to 
polyclonal Tregs, CAR and ΔCAR Tregs transmigrated through HLA-A2+ endothelial monolayers 
significantly faster than through HLA-A2– endothelial monolayers (p=0.042; Figure 3G), suggesting a 
preferential migration into HLA-A2+ target tissues. 
Overall, these results demonstrated that compared to polyclonal Tregs, donor-specific CAR Tregs 
exhibited a greater suppressive capacity in the presence of HLA-A2 without eliciting cytotoxic activity 
and transmigrated at a faster rate through HUVECs expressing HLA-A2. 
 
CAR-mediated Treg allorecognition conferred a functional advantage in preventing skin 
graft rejection 
We have previously demonstrated the superior efficacy of human Tregs with direct allospecificity 
over polyclonal Tregs at reducing alloimmune injury in a human skin xenograft transplant model (19, 
31). To investigate whether CAR Tregs elicited a similar protective role, the same model was 
employed (Figure S4). Human skin was obtained from routine abdominal angioplasty surgery and 
HLA-A2 expression was determined using collagenase-treated skin explants (Figure S5). BRG mice 
were transplanted with HLA-A2+ skin grafts and following skin engraftment, were injected with 
allogeneic CD25-depleted HLA-A2‒ PBMCs ± autologous Tregs. Mice did not exhibit any signs of 
GvHD throughout the experiments (Figure S6A). Skin grafts were explanted and analysed 
histologically for changes in the skin morphology and immune cell infiltration 5 weeks post-PBMC 
transfer (Figure S4B). Cryosections were stained with haemotoxalin and eosin (Figure S6B) or 
analysed by immunofluorescence. 
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Significant alloimmune damage was observed in the grafts of mice which received PBMCs, as 
demonstrated by a high number of Ki67+ keratinocytes (Figure 4A), a loss of CD31+ blood vessel 
integrity and loss of the involucrin-expressing epidermal layer (Figure 4B). Grafts of mice treated 
with PBMCs and Tregs had comparatively fewer Ki67+ keratinocytes (Figure 4A), intact CD31+ blood 
vessels and a defined involucrin layer (62) (Figure 4B). Quantification of these observations 
demonstrated that CAR Treg treatment reduced the number of Ki67+ keratinocytes to basal levels, 
exhibiting significantly more protection than polyclonal Tregs (p=0.042) (Figure 4D). Interestingly, in 
this readout of graft damage, ΔCAR Tregs also mediated superior protection to polyclonal Tregs, 
although statistical significance was not reached (p=0.11). Conversely, when measuring damage in 
terms of CD31+ blood vessel integrity, CAR Tregs (CD31+ cluster size = 88.9 ± 8.5; p<0.0001) mediated 
protection more effectively than both polyclonal (73.3 ± 8.7; p=0.017) and ΔCAR (70.9 ± 10.1; 
p=0.026) Tregs (Figure 4E). Mice which received PBMCs with CAR or ΔCAR Tregs (p<0.0001 versus 
PBMCs alone) had a greater FOXP3:CD3 ratio than mice which received PBMCs with polyclonal Tregs 
(p=0.019). Together, these results suggested that CAR expression facilitated preferential homing and 
retention of the Tregs in the HLA-A2+ allografts. This localisation to the graft enabled the ΔCAR Tregs 
to elicit more protection than polyclonal Tregs, likely due to these cells being activated in a TCR-
dependent manner through direct allorecognition. However, the protection offered was further 
improved upon by the CAR Tregs which were activated in both a TCR-dependent (direct 
allorecognition) and CAR-dependent manner. 
In conclusion, CAR-engineered HLA-A2-specific Tregs inhibited alloimmune-mediated injury against 
HLA-A2+ skin allografts significantly more effectively than polyclonal or ΔCAR Tregs demonstrating 
the increased potency of these cells in vivo and the requirement for Treg signalling to elicit this 
response. 
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Animal models of transplantation have demonstrated that allospecific Tregs are superior to 
polyclonal Tregs at protecting from allograft rejection (4, 17, 19, 31-34). Here, we isolated human 
Tregs using GMP-compatible protocols and used CAR technology to generate donor-MHC class I-
allospecific CAR Tregs which were functionally superior to polyclonal Tregs in vitro and in a human 
skin xenograft transplant model. These results demonstrated a promising new direction for clinical 
trials which are currently assessing the safety and efficacy of polyclonal Treg therapy in kidney (the 
ONE Study: NCT02129881) and liver (ThRIL: NCT02166177) transplant recipients (29, 30). 
Tregs which recognise allo-MHC-peptide complexes (direct allorecognition) and/or allopeptides 
presented in the context of recipient MHC (indirect allospecificity) have been shown to suppress 
alloimmune responses more effectively than polyclonal Tregs (4, 17-19, 31-34). However, the 
potential of CD4+ Tregs is limited as they are MHC class II-restricted thus activated primarily by 
professional APCs. CARs recognise their target antigen in an MHC-independent manner and as such, 
can confer specificity for donor MHC class I, an alloantigen ubiquitously expressed on tissue 
parenchyma throughout an allograft. 
In this study, we selected HLA-A2 as a target antigen due to its comparatively high prevalence 
(>40%) in UK donors (63). The scFv used to construct the HLA-A2-specific CAR cross-reacts with HLA-
A28 and HLA-A68 (50). CARs which cross-react with various HLA alleles can be used in a wide variety 
of donor-recipient combinations thus we believe that generating a library of HLA class I-specific CARs 
using cross-reactive scFvs will allow for an efficient adaptation into the clinic. Furthermore, we 
demonstrated that these CARs can be efficiently delivered into human Tregs by lentiviral 
transduction which is currently employed clinically to deliver CD19-specific CARs into Teffs for the 
treatment of CLL (37, 38). Progress based on the CRISPR/Cas9 system may make more directed and 
safer gene delivery accessible in the near future (33). 
CAR Tregs demonstrably protected HLA-A2+ human skin grafts more effectively than polyclonal 
Tregs. However, interesting results were also obtained for the ΔCAR Tregs. These cells exhibited a 
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favoured migration and retention in HLA-A2+ target tissues which enabled the elicitation of greater 
graft protection than polyclonal Tregs. However, in terms of CD31+ blood vessel integrity, the 
protection offered by the ΔCAR Tregs was not as great as the CAR Tregs. These findings suggested 
that the Treg localisation was an important factor in determining the protection offered, particularly 
as TCR-mediated direct allorecognition could facilitate activation of these cells in the graft. However, 
to exploit the full potential of CAR technology, a functional CAR which activated Tregs in the 
presence of HLA-A2 was required. 
Although CARs have principally been used to generate cancer-specific Teffs, studies investigating the 
therapeutic potential of CAR Tregs have been performed. Very recently, the efficacy of human CAR 
Tregs was demonstrated in the prevention of xeno-GvHD (49). Furthermore, in pre-clinical models of 
colitis (16, 44, 45) and multiple sclerosis (46), CAR Tregs were found to migrate to locations where 
their cognate antigen was expressed and suppress undesired immune responses more effectively 
than polyclonal Tregs. Similarly, we have shown that CAR Tregs redirected towards HLA-A2 
preferentially transmigrate through alloantigen-expressing endothelial cells and exhibit a favoured 
homing and retention in allografts. These observations suggest a clinical potential for CAR Tregs 
outside of the transplant field, particularly in light of ongoing clinical trials which are assessing the 
safety and efficacy of polyclonal Treg therapy for the treatment of Type I diabetes (NCT01210664) 
(27), lupus erythematosus (NCT02428309) and uveitis (NCT02494492). 
In conclusion, polyclonal Treg therapy is currently being investigated clinically by us and others as a 
means of limiting graft rejection. However, to avoid the risk of pan-immunosuppression and provide 
a tailored therapy, the successful generation and expansion of alloantigen-specific Tregs is required. 
We demonstrated that clinically-applicable CAR technology may be used to generate donor antigen-
specific Tregs which suppress alloimmune responses, providing a future direction for Treg therapy in 
the pursuit of transplant tolerance in solid organ transplantation. 
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FIGURE LEGENDS 
Figure 1: CD4+CD25– T cells expressing the full-length CAR were activated in the presence of HLA-
A2+ cells. A-B: Schematic diagrams detailing the components of the CAR genes. A CAR-eGFP fusion 
protein was generated consisting of a HLA-A2-specific scFv (white), a CD28 hinge/transmembrane 
(TM) domain (grey), a CD28/CD3ζ signalling domain (light grey) and an eGFP reporter gene (grey 
dots). A control CAR (ΔCAR) comprising the same elements but no signalling domain was also 
generated. C: Transduction efficiency of CD4+CD25– Teffs, prior to cell sorting, as determined by flow 
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cytometry analysing eGFP expression. Data is representative of 4 individual experiments. D: Flow 
cytometry histogram plots showing the expression of HLA class I, HLA-DR and HLA-A2 (BB7.2 or 
REA142 clone) by MCF-7 (solid line) and T-47D (dotted line), compared to an isotype control (solid 
grey). E: Macroscopic images of MCF-7 and T-47D monolayers following overnight co-culture with 
untransduced (UN-TDX), CAR or ΔCAR T cells. Representative data of 4 individual experiments. F: 
Quantification of MCF-7 (HLA-A2+, black) and T-47D (HLA-A2–, grey) viability following overnight co-
culture with untransduced, CAR or ΔCAR T cells as measured by MTT assay. Percent viability is 
relative to monolayers cultured alone. IL-2 (G) and IFNγ (H) production by the T cells during co-
culture with cell monolayers, as measured by ELISA. Data shown is mean ± SEM pooled from 4 
individual experiments and significance was determined by two-tailed paired Student’s t-test where 
*=p<0.05 and ****=p<0.0001. ND = not detected. 
 
Figure 2: Human CD4+CD25+ Tregs maintained their phenotype and function following CAR 
lentiviral transduction and cell sorting. A: Timeline showing production of human CAR Tregs used 
for experimentation. B: Representative flow cytometry data showing the proportion of Tregs which 
were successfully transduced (eGFP expression) and the proportion of cells co-expressing the 
CAR/ΔCAR construct on the cell surface (c-Myc expression) immediately before and after eGFP+ cell 
sorting. C: Representative flow cytometry data showing the recognition of a HLA-A2 or HLA-B7 
(irrelevant)-based dextramer by untransduced, CAR and ΔCAR Tregs. D: Activation of untransduced, 
CAR and ΔCAR Tregs following co-culture with HLA-A2+ APCs (solid line), HLA-A2– APCs (dotted line) 
or no APCs (solid grey). Tregs were co-cultured with K562 cells or B-LCLs as APCs for 18 hours at a 4:1 
Treg:APC ratio after which Treg activation was measured by CD69 expression. K562s were stably 
transfected to express either HLA-A2 or HLA-A1. SPO (HLA-A2+) and BM21 (HLA-A2–) B-LCLs were 
used. Data shown is representative of 2 individual experiments. E: Pooled flow cytometry data 
comparing the expression of typical Treg markers by untransduced (black), CAR (light grey) and ΔCAR 
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(dark grey) Tregs. Data shown is mean ± SD pooled from 5 individual experiments. F: Pooled flow 
cytometry data comparing the expression of select skin, gut and secondary lymphoid organ homing 
receptors by untransduced (black), CAR (light grey) and ΔCAR (dark grey) Tregs. Data shown is mean 
± SD pooled from 5 individual experiments. G: Polyclonal suppression assay comparing the 
suppressive capacity of untransduced (black line), CAR (light grey line) and ΔCAR (dark grey line) 
Tregs. Tregs and autologous Teffs activated in a polyclonal manner were co-cultured at differing 
ratios for 5 days after which Teff proliferation was measured by CellTrace Violet dilution. Data is 
expressed as percentage of inhibition of responder Teff proliferation, relative to Teffs cultured 
alone. Data shown is mean ± SEM pooled from 5-6 individual experiments. 
 
Figure 3: Human CAR Tregs functioned more effectively in the presence of HLA-A2 without eliciting 
cytotoxicity. The suppressive capacity of untransduced (A), CAR (B) and ΔCAR (C) Tregs in the 
presence of HLA-A2+ B-LCLs (black line) or HLA-A2– B-LCLs (grey line). Data shown is mean ± SEM 
pooled from 5 individual experiments. D: Quantification of MCF-7 (black) and T-47D (grey) viability 
following overnight co-culture with untransduced, CAR or ΔCAR Tregs as measured by MTT assay. 
Percent viability is relative to monolayers cultured alone. IFNγ (E) and IL-10 (F) production by the 
Tregs during co-culture with cell monolayers, as measured by ELISA. Data shown is mean ± SEM 
pooled from 3-4 individual experiments. Significance was determined by two-tailed paired Student’s 
t-test where *=p<0.05. ND = not detected. G: Transmigratory capacity of CAR (black) and ΔCAR 
(grey) Tregs across IFNγ pre-treated HLA-A2– and HLA-A2+ HUVEC endothelial cell monolayers. Data 
shown represents the percentage of CAR and ΔCAR Tregs which transmigrated, relative to 
untransduced (UN-TDX) Tregs. Data shown in mean ± SEM pooled from 2-6 individual experiment. 
Significance was determined by two-way ANOVA where *=p<0.05. 
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Figure 4: Human CAR Tregs inhibited alloimmune-mediated injury of human HLA-A2+ skin grafts 
more effectively than polyclonal Tregs. Immunodeficient BRG mice which had received a HLA-A2+ 
human skin graft were injected with 5x106 PBMCs ± 1x106 Tregs. Control mice received saline only. 
Human skin grafts were removed 5 weeks post-injection and cryopreserved sections were fixed and 
stained either for human CD45/Ki67/DAPI (A), CD31/Involucrin/DAPI (B) or human FOXP3/human 
CD3/DAPI (C). Images are representative immunofluorescence stains of human skin grafts. 
Quantification of the number of Ki67+ keratinocytes (D), CD31+ cluster size (E) and FOXP3:CD3 ratio 
(F) per field of view was performed using NIS Elements and FIJI imaging software (51). Results 
represent 2-3 mice/group where 4-6 fields of view were quantified per section and data is 
representative of 2 individual experiments. Significance was determined by one-way ANOVA and the 
Tukey multiple comparison post-hoc test where *=p<0.05, **=p<0.01, ***=p<0.001 and 
****=p<0.0001. ns = not significant. 
 
SUPPORTING INFORMATION 
Additional Supporting Information may be found in the online version of this article. 
Figure S1: Isolation purity of human CD4+CD25+ Tregs. A: Following isolation, Tregs were co-stained 
for CD4 (OKT4) and CD25 (4E3) and the purity was determined by flow cytometry to be 96.2%. Data 
is representative of 15 individual experiments. B: Following live/dead discrimination, cells were 
assessed for expression of the following markers by flow cytometry: CD4 (OKT4), CD25 (4E3), CD127 
(A019D5), FOXP3 (PCH101), CTLA-4 (BNI3) and CD39 (eBioA1). Data shown is mean ± SD pooled from 
6 individual experiments. 
Figure S2: Proliferation of Tregs in the presence of HLA-A2+ and HLA-A2– APCs. Proliferation of 
untransduced (red), CAR (blue) and ΔCAR (green) Tregs following co-culture with HLA-A2+ and HLA-
A2– APCs. Tregs were co-cultured with K562 cells (A) or B-LCLs (B) as APCs for 72 hours at a 1:1 ratio. 
Treg proliferation was measured by 3H-thymidine incorporation and is shown in cpm (counts per 
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minute) where the cpm of APCs cultured alone was subtracted. K562s were stably transfected to 
express either HLA-A2 or HLA-A1. SPO (HLA-A2+) and BM21 (HLA-A2–) B-LCLs were used. Data shown 
is mean ± SD and is representative of 2 individual experiments. Significance was determined by two-
tailed paired Student’s t-test where *=p<0.05. ns = not significant. 
Figure S3: Detailed phenotypic analysis of transduced human Tregs. Representative flow cytometry 
plots comparing the expression of typical Tregs markers (A) and various homing receptors (B) by 
untransduced (UN-TDX; red line) CAR (blue line) and ΔCAR (green line) Tregs. Isotype control staining 
is shown in solid grey. Data shown is representative of 5 individual experiments. 
Figure S4: Schematic diagrams detailing the experimental design of the human skin xenograft 
transplant experiments. A: Human skin from HLA-A2+ donors was transplanted onto recipient 
immunodeficient BRG mice and allowed to engraft for 5-6 weeks. These mice were then injected 
intravenously with allogeneic HLA-A2‒ PBMCs with or without autologous ex vivo-expanded Tregs. 
Mice were sacrificed 5 weeks following PBMC infusion and skin grafts were monitored histologically 
for changes in skin morphology and cell infiltration. B: Timeline showing when mice were 
transplanted with human skin, injected with allogeneic PBMCs ± Tregs and sacrificed to analyse skin 
graft histology. 
Figure S5: HLA-A2 expression on skin-derived cells. Small explants of human skin were tested for 
HLA-A2 expression by flow cytometry prior to transplantation. Cells acquired by treating explants 
with collagenase for 1 hour were stained with two separate HLA-A2-specific antibody clones (BB7.2 
and REA142 denoted by blue and green lines, respectively). HLA-A2-expression was compared to 
cells stained with an isotype control, shown in solid grey. 
Figure S6: Mice transplanted with human skin allografts did not lose weight following PBMC 
transfer. A: Transplanted mice injected with allogeneic PBMCs ± Tregs showed no signs of graft-
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versus-host disease and no weight loss. B: Representative haematoxylin/eosin stains of skin grafts 
stained in Figure 4. 
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